Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth [PDF]
Therapeutic Advances in Medical Oncology, 2020 Background: Merkel cell carcinoma (MCC) is a highly malignant skin cancer. Despite major treatment improvements during the last decade, up to 50% of patients do not respond to therapy or develop recurrent disease.
Emil Chteinberg +10 more
doaj +4 more sources
Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia [PDF]
Blood AdvancesNicholas J. Short +16 more
doaj +3 more sources
CPT: Pharmacometrics & Systems PharmacologyNavitoclax, an oral small molecule BCL‐XL/BCL‐2 inhibitor evaluated in myelofibrosis, was assessed through integrated PK/PD modeling to guide starting dose and dose‐reduction decisions when combined with ruxolitinib.
Akshanth R. Polepally +7 more
doaj +2 more sources
HeliyonAlzheimer's disease (AD) is the most common global dementia and is universally fatal. Most late-stage AD disease-modifying therapies are intravenous and target amyloid beta (Aβ), with only modest effects on disease progression: there remains a high unmet
Edward F. Greenberg +28 more
doaj +3 more sources
Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells [PDF]
Antioxidants, 2020 Melatonin (N-acetyl-5-methoxytryptamine MEL) is an indolamine that has antioxidant, anti-inflammatory and anti-tumor properties. Moreover, MEL is capable of exhibiting both anti-apoptotic and pro-apoptotic effects.
Alexey Lomovsky +7 more
doaj +3 more sources
Targeting PIK3CB/YAP1 improves the sensitivity of paclitaxel by suppressing aging in head and neck squamous tumor cells [PDF]
Cancer Cell InternationalBackground Tumor cell senescence reduces sensitivity to anticancer drugs, making senescent cell elimination an ideal strategy to enhance chemotherapy sensitivity.
Junzhi Liu +4 more
doaj +2 more sources
The Role of Navitoclax in Myelofibrosis [PDF]
Cureus, 2021 Primary myelofibrosis (PMF) is the most aggressive type of chronic myeloproliferative neoplasm, characterized by a disarray of hematopoietic stem cells and bone marrow fibrosis. The estimated incidence is 1.5 per 100,000 individuals per year with a median survival of less than six years.
Pandravada, Sasirekha, Sandler, Steven
openaire +3 more sources
Targeting BCL-xL in Myeloid Malignancies: From Inhibitors to PROTAC. [PDF]
J Cell Mol MedABSTRACT Restoring apoptosis in malignant cells represents a central goal of anticancer therapy. Tumour cells often escape cell death by overexpressing anti‐apoptotic members of the BCL‐2 protein family, particularly BCL‐2, BCL‐xL, and MCL1. These proteins inhibit the intrinsic mitochondrial apoptotic pathway through intricate interactions with pro ...
Cilloni D, Ferrando A, Frassoni F.
europepmc +2 more sources
Identification and Validation of cGAS-STING Pathway-Associated Predictive and Therapeutic Models for Esophageal Squamous Cell Cancer Patients via Artificial Intelligence and Multi-Omics. [PDF]
Cancer MedABSTRACT Background Esophageal squamous cell cancer (ESCC) is a malignancy derived from the Esophagus, and dysregulation of the cGAS‐STING pathway contributes to ESCC progression. Method ESCC bulk‐seq dataset GSE38129 was acquired from GEO database and then underwent Limma and WGCNA analysis for the identification of shared DEGs, which were intersected
Zhou C, Liu X, Wang Z, Yang T.
europepmc +2 more sources
Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax [PDF]
Neuro-Oncology Advances, 2021 Abstract Background Malignant meningioma is an aggressive tumor that requires adjuvant radiotherapy after surgery, yet there has been no standard systemic therapy established so far. We recently reported that malignant meningioma cells are highly sensitive to gemcitabine; however, it remains unknown ...
Masahiro Yamamoto +8 more
openaire +2 more sources